P1263: A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES

• L. Hebert,
• P. Shah,
• O. Diaz,
• A. A. Street,
• J. Li,
• E. Rudenko,
• A. M. Zlotnicki,
• C. Morrison,
• R. Bomben,
• Y. Huang,
• A. Medina Herrera,
• A. Wong,
• S. Gleen

Affiliations

L. Hebert

1 R&D

P. Shah

1 R&D

O. Diaz

1 R&D

A. A. Street

1 R&D

J. Li

1 R&D

E. Rudenko

1 R&D

A. M. Zlotnicki

2 BioInformatics, Invivoscribe, San Diego

C. Morrison

3 Center for Personalized Medicine, Roswell Park Cancer Institute, Buffalo, United States of America

R. Bomben

4 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Aviano, Italy

Y. Huang

1 R&D

A. Medina Herrera

5 Biología molecular y celular de hemopatías, Hospital Universitario de Salamanca, Salamanca, Spain

A. Wong

6 Lahey Hospital, Lahey Hospital & Medical Center, Burlington, United States of America

S. Gleen

3 Center for Personalized Medicine, Roswell Park Cancer Institute, Buffalo, United States of America